Table 1.
Baseline characteristics of the training set and two test sets.
| HPPH training set | HPPH test set | HPCH test set | ||||
|---|---|---|---|---|---|---|
| HCC | Non-HCC | HCC | Non-HCC | HCC | Non-HCC | |
| Patients | 647 | 6865 | 218 | 167 | 264 | 292 |
| Male | 509 | 3710 | 168 | 45 | 214 | 101 |
| Female | 138 | 3155 | 50 | 122 | 50 | 191 |
| Age (years) | 57.36 (8–86) | 54.19 (2–93) | 56.38 (17–87) | 52.42 (20–84) | 55.43 (28–82) | 53.74 (17–90) |
| Age ≤60 years male | 320 (49.46%) | 2314 (33.71%) | 115 (52.75%) | 38 (22.75%) | 149 (56.44%) | 56 (19.18%) |
| Age >60 years male | 189 (29.21%) | 1396 (20.34%) | 53 (24.31%) | 7 (4.19%) | 65 (24.62%) | 45 (15.41%) |
| Age ≤60 years female | 58 (8.96%) | 2045 (29.79%) | 27 (12.39%) | 92 (55.09%) | 24 (9.09%) | 142 (48.63%) |
| Age >60 years female | 80 (12.36%) | 1110 (16.17%) | 23 (10.55%) | 30 (17.96%) | 26 (9.85%) | 49 (16.78%) |
| Non-HCC disease variety | ||||||
| Intrahepatic cholangiocarcinoma | -- | 59 | -- | 0 | -- | 0 |
| Liver metastasis | -- | 271 | -- | 5 | -- | 205 |
| Sarcoma | -- | 9 | -- | 0 | -- | 0 |
| Hepatic hemangioma | -- | 1896 | -- | 119 | -- | 49 |
| Focal nodular hyperplasia | -- | 23 | -- | 0 | -- | 1 |
| Angioleiomyolipoma | -- | 16 | -- | 0 | -- | 0 |
| Hepatic adenoma | -- | 13 | -- | 0 | -- | 0 |
| Liver abscess | -- | 36 | -- | 7 | -- | 3 |
| Hepatic cyst | -- | 1097 | -- | 36 | -- | 16 |
| Neuroendocrine neoplasm | -- | 24 | -- | 0 | -- | 18 |
| Normal | -- | 3421 | -- | 0 | -- | 0 |
| Surgery or biopsy pathology | 425 (65.7%) | 1184 (17.2%) | 218 (100.00%) | 167 (100.00%) | 264 (100.00%) | 292 (100.00%) |